US · GDTC
CytoMed Therapeutics Limited
- Sector
- Healthcare · Biotechnology
- Headquarters
- Singapore 149544
- Website
- w2.cytomed.sg
Price · as of 2024-12-31
$0.97
Market cap 12.67M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $49.39 | +4,973.45% |
| Intrinsic Value(DCF) | $1.22 | +25.32% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $11.50 | +1,081.72% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $0.00 | $0.00 | |||
| 2022 | |||||
| 2023 | $2.06 | $0.27 | $0.00 | ||
| 2024 | $2.71 | $49.39 | $0.23 | $0.00 | $11.50 |
AI valuation
Our deep-learning model estimates CytoMed Therapeutics Limited's (GDTC) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $49.39
- Current price
- $0.97
- AI upside
- +4,973.45%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$1.22
+25.32% upside
Graham-Dodd
—
— upside
Graham Formula
$11.50
+1,081.72% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| GDTC | CytoMed Therapeutics Limi… | $0.97 | 12.67M | +4,973% | +25% | — | +1,082% | -16.97 | 4.76 | 601.35 | -15.62 | — | 4.81 | 100.72% | -5049.84% | -3621.15% | -24.43% | -98.92% | -22.01% | 0.05 | -172.79 | 9.89 | 8.22 | 1.84 | -4483.00% | -8210.00% | 1064.00% | -9.62% | -4.47 | -113.37% | 0.00% | 0.00% | 0.00% | -10.65 | -9.29 | 537.89 | 22.44 |
| CLGN | CollPlant Biotechnologies… | $0.57 | 7.18M | +8,539% | +137% | — | +21,233% | -2.30 | 2.84 | 74.26 | -1.89 | -1.72 | 2.87 | -417.09% | -3349.71% | -3225.05% | -79.46% | -364.64% | -62.87% | 0.23 | -1014.76 | 4.44 | 4.21 | 0.57 | 13387.00% | -9530.00% | 29214.00% | -38.11% | -4.75 | -308.10% | 0.00% | 0.00% | 0.00% | -1.71 | -2.02 | 57.12 | -6.47 |
| ENLV | Enlivex Therapeutics Ltd. | $1.15 | 27.95M | — | — | — | — | -1.63 | 1.03 | — | -0.09 | — | 1.03 | 0.00% | — | — | -55.95% | -720.93% | -46.54% | 0.02 | -1195.08 | 6.84 | 6.56 | 0.19 | -5321.00% | — | -4482.00% | -53.71% | -3.42 | -608.40% | 0.00% | 0.00% | 12.23% | -0.09 | -0.10 | — | -3.74 |
| LSTA | Lisata Therapeutics, Inc. | $4.10 | 36.16M | — | -69% | — | — | -0.98 | 0.66 | 19.66 | 0.52 | — | 0.67 | 100.00% | -2240.90% | -1998.50% | -51.43% | 1147.42% | -44.56% | 0.00 | — | 6.16 | 5.73 | 0.72 | -698.00% | — | -337.00% | -98.47% | -3.45 | 1030.67% | 0.00% | 0.00% | 0.00% | 0.51 | 0.59 | -11.45 | -20.94 |
| MTVA | MetaVia Inc. | $1.51 | 3.32M | — | — | — | — | -0.44 | 1.52 | — | 0.13 | -0.97 | 1.52 | 0.00% | — | — | -224.18% | 426.89% | -141.35% | 0.02 | — | 1.94 | 1.94 | 0.55 | 4472.00% | — | 12784.00% | -205.58% | -2.99 | 366.27% | 0.00% | 0.00% | 0.00% | 0.13 | 0.16 | — | -16.10 |
| NCNA | NuCana plc | $2.16 | 13.12M | — | — | — | — | -41.51 | 132.44 | — | -34.78 | — | 210.00 | 0.00% | — | — | -182.30% | 1515.50% | -89.22% | 0.03 | — | 1.42 | 1.31 | 0.29 | -3771.00% | — | -2789.00% | -2.46% | -2.21 | 1524.22% | 0.00% | 0.00% | 0.00% | -34.28 | -40.29 | — | 27.59 |
| NRSN | NeuroSense Therapeutics L… | $0.91 | 22.42M | — | — | — | — | -2.06 | 8.14 | — | -1.79 | — | 8.14 | 0.00% | — | — | -2880.11% | 388.77% | -263.45% | 0.03 | -31.84 | 2.21 | 1.78 | 0.33 | -3373.00% | — | 2094.00% | -48.23% | -5.09 | 398.04% | 0.00% | 0.00% | 3.84% | -1.79 | -1.75 | — | -11.40 |
| PASG | Passage Bio, Inc. | $9.12 | 28.99M | — | — | — | — | -0.43 | 0.45 | — | 0.38 | — | 0.45 | 0.00% | — | — | -75.07% | -423.28% | -51.21% | 0.42 | — | 4.07 | 3.96 | 0.19 | -4250.00% | — | -3880.00% | -172.71% | -2.48 | -288.54% | 0.00% | 0.00% | 60.04% | 0.33 | 0.49 | — | -10.18 |
| SONN | Sonnet BioTherapeutics Ho… | $1.26 | 8.43M | +87,488% | -33% | — | +67,885% | -0.19 | -2.83 | 73.88 | -0.12 | — | -2.83 | 100.00% | -63617.91% | -39929.30% | 2089.93% | 846.19% | -181.38% | -0.27 | — | 0.66 | 0.28 | 0.00 | -9218.00% | -8740.00% | -6049.00% | -625.56% | -2.68 | 614.69% | 0.00% | 0.00% | 0.00% | -0.11 | -0.16 | 72.88 | -73.78 |
| XCUR | Exicure, Inc. | $3.74 | 23.84M | — | +24% | — | — | -7.29 | 10.45 | 141.51 | -7.25 | — | 10.45 | 100.00% | -2446.40% | -1940.20% | -197.92% | -269.46% | -72.84% | 0.88 | -679.56 | 4.45 | 4.24 | 0.74 | -2464.00% | — | -7190.00% | -4.11% | -0.95 | -64.10% | 0.00% | 0.00% | 17.56% | -5.25 | -22.06 | 128.36 | -15.21 |
About CytoMed Therapeutics Limited
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.
- CEO
- Chee Kong Choo
- Employees
- 43
- Beta
- -0.12
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($1.22 ÷ $0.97) − 1 = +25.32% (DCF, example).